Norbert Brüggemann
Norbert Brüggemann, MD
Research section leader
Phone number:+49 451 500 43420

Current Positon:

Neurogenetics Faculty

Research Focus:

Genetics of movement disorders with a focus on dystonia and Parkinson’s disease; Sensorimotor control of actions and movement disorders; Multimodal in-vivo mapping (fMRI, TMS) of human brain networks; Transcranial sonography

Education & Scientific training

Education:

1998-2005 Medical School at the University of Lübeck

2001-2005 Doctoral thesis at the University of Lübeck, Institute of Clinical and Experimental Pharmacology and Toxicology (Director: Prof. Dr. P. Dominiak), Topic: „Regulation of the expression of orexin receptors by gonadal steroids“ (Dr. med., summa cum laude)

2005-2010 Clinical Training as Medical Doctor at the Department of Neurology, University Clinic of Schleswig-Holstein, Campus Lübeck

2011 Clinical Training as Medical Doctor at the Department of Psychiatry and Psychotherapy, University Clinic of Schleswig-Holstein, Campus Lübeck

01/2012 Habilitation in Neurogenetics at the University of Lübeck, Private Lecturer for Neurogenetics (Priv.-Doz.), Topic: „Characterization of Hereditary Parkinsonian Syndromes using Clinical, Genetic and Imaging Methods“

Scientific Training:

2001-2005 Institute of Clinical and Experimental Pharmacology and Toxicology (University of Lübeck), supervised by Priv.-Doz. Dr. O. Jöhren
Studies on the expression of orexin receptors in rodents

2005-2011 Institute of Neurogenetics (University of Lübeck), supervised by Prof. Dr. C. Klein
Genetics of movement disorders

2011-current Danish Research Centre for Magnetic Resonance (Copenhagen University Hospital Hvidovre, Denmark), supervised by Prof. Dr. H. R. Siebner
Sensorimotor control of actions

Awards & Memberships

Awards:

2002 – 2005 Scholarship of the German Catholic Academic Foundation „Cusanuswerk“

2006 National University Award of the Medical Faculty, University of Lübeck

2008 Travel grant from the Movement Disorder Society

2009 Travel grant from the American Academy of Neurology

2010 Travel grant from the American Academy of Neurology

2011 Travel grant from the Movement Disorder Society

2012 Travel grant from the Movement Disorder Society

2012 Junior Research Award of the Movement Disorder Society

Memberships:

Movement Disorders Society (MDS)

German Neurological Society (DGN)

German Society of Clinical Neurophysiology and Functional Imaging (DGKN)

Working Group botulinum toxin of the German Neurological Society (Arbeitskreis Botulinumtoxin der Deutschen Gesellschaft für Neurologie)

Research Funding

Title: “Role of the ATP13A2 gene in the pathogenesis of parkinsonism“

Principal Investigator
Agency: Intramural Funding of the Medical Faculty, University of Lübeck
Type: Research Grant
Funding period: 2009-2010
Amount: 57,000 €

Title: “Transcranial ultrasonographic evaluation of the basal ganglia in DYT1, DYT11 and DYT12 dystonia”

Co- Investigator (Principal Investigators: R. Saunders-Pullman, MD; J. Hagenah, MD)
Agency: Bachmann Strauss Dystonia & Parkinson Foundation
Type: Research Grant
Funding period: 2011
Amount: 50,000 USD

Title: “Endophenotypes of Movement Disorders”

Principal Investigator (2nd PI: of the Lübeck site C. Klein, MD + 2 PIs from the Kiel site) of a subproject on endophenotypes of essential tremor and Parkinson’s disease
Agency: Medizinausschuss Schleswig-Holstein
Type: Research Grant
Funding period: 2011
Amount: 12,000 €

Title: “Modulation of response inhibition mechanism of action control: a combined TMS-fMRI study in healthy individuals”

Principal Investigator
Agency: German Research Foundation (DFG)
Type: Post-doctoral Fellowship Grant
Funding period: 2011-2013
Amount: 50,000 €

Publications

Selection of 5 most important publications out of 48; cumulative impact factor: 249.9; mean 5.2

  1. Brüggemann N, Kock N, Lohmann K, König IR, Rakovic A, Hagenah J, Schmidt A, Ziegler A, Jabusch HC, Siebner H, Altenmüller E, Münchau A, Klein C. The D216H variant in the DYT1 gene - a susceptibility factor for dystonia in familial cases? Neurology 2009;72:1441-3.

  2. Brüggemann N, Hagenah J, Reetz K, Schmidt A, Kasten M, Buchmann I, Eckerle S, Bähre M, Münchau A, Djarmati A, van der Vegt J, Siebner H, Binkofski F, Ramirez A, Behrens MI, Klein C. Recessively inherited parkinsonism: effect of ATP13A2 mutations on the clinical and neuroimaging phenotype. Arch Neurol 2010;67:1357-1363.

  3. Hagenah J, König IR, Sperner J, Wessel L, Seidel G, Condefer K, Saunders-Pullman, Klein C, Brüggemann N. Life-long increase of substantia nigra hyperechogenicity in transcranial sonography. Neuroimage 2010;51:28-32.

  4. Brüggemann N, Hagenah J, Stanley K, Klein C, Wang C, Raymond D, Ozelius L, Bressman S, Saunders-Pullman R. Substantia nigra hyperechogenicity with LRRK2 G2019S mutations. Mov Disord 2011;26:885-888.

  5. Brüggemann N, Spiegler J, Hellenbroich Y, Opladen T, Schneider SA, Boor R, Stephani U, Gillessen-Kaesbach G, Sperner J, Klein C. Beneficial prenatal levodopa therapy in autosomal recessive GTP cyclohydrolase I deficiency. Arch Neurol 2012;69:1071-1075.

Complete list of publications
  1. Jöhren O, Brüggemann N, Dendorfer A, Dominiak P. Gonadal steroids differentially regulate the messenger ribonucleic acid expression of pituitary orexin type 1 receptors and adrenal orexin type 2 receptors. Endocrinology 2003;144:1219-1225.

  2. Jöhren O, Brüggemann N, Dominiak P. Orexins (hypocretins) and adrenal function. Hormone and Metabolic Research 2004;36:370-375.

  3. Schmidt A, Jabusch HC, Altenmüller E, Hagenah J, Brüggemann N, Hedrich K, Saunders-Pullman R, Bressman SB, Kramer PL, Klein C. Dominantly transmitted focal dystonia in families of patients with musician's cramp. Neurology 2006;67:691-693.

  4. Lohmann-Hedrich K, Brüggemann N, Hagenah J, Klein C. Das Parkinson-Syndrom und seine genetischen Ursachen – eine Standortbestimmung. Aktuelle Neurologie 2007;34:151-161.

  5. Brueggemann N, Doegnitz L, Harms L, Moser A, Hagenah J. Skin reactions after intramuscular injection of Botulinum toxin A: A rare side effect. J Neurol Neurosurg Psychiatry 2008;79:231-232.

  6. Brueggemann N, Odin P, Gruenewald A, Tadic V, Hagenah J, Seidel G, Lohmann K, Klein C, Djarmati A; De novo a-Synuclein duplication as cause of sporadic early onset parkinsonism. Neurology 2008;71:1294.

  7. Hagenah JM, Becker B, Brüggemann N, Djarmati A, Lohmann K, Sprenger A, Klein C, Seidel G. Transcranial sonography findings in a large familiy with homo- and heterozygous PINK1 mutations. J Neurol Neurosurg Psychiatry 2008;79:1071-1074.

  8. Seibler P, Djarmati A, Langpap B, Hagenah J, Schmidt A, Brüggemann N, Siebner H, Jabusch HC, Altenmüller E, Münchau A, Lohmann K, Klein C. Heterozygous nonsense mutation in the PRKRA (DYT16) gene associated with generalized dystonia. Lancet Neurol 2008; 7:380-381.

  9. Brüggemann N, Kock N, Lohmann K, König IR, Rakovic A, Hagenah J, Schmidt A, Ziegler A, Jabusch HC, Siebner H, Altenmüller E, Münchau A, Klein C. The D216H variant in the DYT1 gene - a susceptibility factor for dystonia in familial cases? Neurology 2009;72:1441-1443.

  10. Brüggemann N, Mitterer M, Lanthaler AJ, Djarmati A, Hagenah J, Wiegers K, Winkler S, Pawlack H, Lohnau T, Pramstaller PP, Klein C, Lohmann K. Frequency of heterozygous Parkin mutations in healthy subjects: Need for careful prospective follow-up examination of mutation carriers. Parkinsonism Relat Disord 209;15:425-429.

  11. Djarmati A, Hagenah J, Reetz K, Winkler S, Behrens MI, Pawlack H, Lohmann K, Ramirez A, Tadić V, Brüggemann N, Berg D, Siebner HR, Lang AE, Pramstaller PP, Binkofski F, Kostić VS, Volkmann J, Gasser T, Klein C. ATP13A2 variants in early-onset Parkinson's disease patients and controls. Mov Disord 2009;24:2104-2111.

  12. Djarmati A, Schneider SA, Lohmann K, Winkler S, Pawlack H, Hagenah J, Brüggemann N, Zittel S, Fuchs T, Rakovic A, Schmidt A, Jabusch HC, Wilcox R, Kostic VS, Siebner H, Altenmüller E, Münchau A, Ozelius LJ, Klein C. Mutations in THAP (DYT6) and generalized dystonia with prominent spasmodic dysphonia: a genetic screening study. Lancet Neurol 2009;8:447-452.

  13. Schmidt A, Jabusch HC, Altenmüller E, Hagenah J, Brüggemann N, Lohmann K, Enders L, Kramer PL, Saunders-Pullman R, Bressman SB, Münchau A, Klein C. Etiology of musician’s dystonia: Familial or environmental? Neurology 2009; 72:1248-1254.

  14. Zschiedrich K, König IR, Brüggemann N, Kock N, Kasten M, Leenders KL, Kostić V, Vieregge P, Ziegler A, Klein C, Lohmann K. MDR1 variants and risk of Parkinson disease: Association with pesticide exposure? J Neurol 2009;256:115-120.

  15. Behrens MI, Brüggemann N, Chana P, Venegas P, Kägi M, Parrao T, Orrelana P, Garrido C, Rojas CV, Hauke J, Hahnen E, Gonzalez R, Seleme N, Fernandez V, Schmidt A, Binkofski F, Kömpf D, Kubisch C, Hagenah J, Klein C, Ramirez A. Clinical spectrum of Kufor Rakeb Syndrome in the Chilean kindred with ATP13A2 mutations. Mov Disord 2010;25:1929-1937.

  16. Brüggemann N, Gottschalk S, Holl-Ulrich K, Stewen J, Heide W, Seidel G. Cranial pachymeningitis: a rare neurological syndrome with heterogeneous etiology. J Neurol Neurosurg Psychiatry 2010;81:294-298.

  17. Brüggemann N, Hagenah J, Reetz K, Schmidt A, Kasten M, Buchmann I, Eckerle S, Bähre M, Münchau A, Djarmati A, van der Vegt J, Siebner H, Binkofski F, Ramirez A, Behrens MI, Klein C. Recessively inherited parkinsonism: effect of ATP13A2 mutations on the clinical and neuroimaging phenotype. Arch Neurol 2010;67:1357-1363.

  18. Brüggemann N, Schneider SA, Sander T, Klein C, Hagenah J. Distinct basal ganglia hyperechogenicity in idiopathic basal ganglia calcification. Mov Disord 2010;25:2661-2664.

  19. Eggers C, Schmidt A, Hagenah J, Brüggemann N, Klein JC, Tadic V, Kertelge L, Kasten M, Binkofski F, Siebner H, Neumaier B, Fink GR, Hilker R, Klein C (2010) Progression of subtle motor signs in PINK1 mutation carriers with mild dopaminergic deficit. Neurology 2010;74:1798-1805.

  20. Hagenah J, König IR, Sperner J, Wessel L, Seidel G, Condefer K, Saunders-Pullman, Klein C, Brüggemann N. Life-long increase of substantia nigra hyperechogenicity in transcranial sonography. Neuroimage 2010;51:28-32.

  21. Kasten M, Brüggemann N, Schmidt A, Klein C, Weintraub D, Siderowf AD, Xie SX. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 2010;75:478-479.

  22. Kertelge L, Brüggemann N, Schmidt A, Tadic V, Wisse C, Dankert S, Drude L, van der Vegt J, Siebner H, Pawlack H, Pramstaller PP, Behrens MI, Ramirez A, Reichel D, Buhmann C, Hagenah J, Klein C, Lohmann K, Kasten M. Impaired sense of smell and color discrimination in monogenic and idiopathic Parkinson disease. Mov Disord 2010;25:2665-2669.

  23. Machner B, Sprenger A, Behrens MI, Ramirez A, Brüggemann N, Klein C, Helmchen C. Eye movement disorders in ATP13A2 mutation carriers (PARK9). Mov Disord 2010;25:2687-2689.

  24. Reetz K, Tadic V, Kasten M, Brüggemann N, Schmidt A, Hagenah J, Pramstaller PP, Ramirez A, Behrens MI, Siebner HR, Klein C, Binkofski F. Structural imaging in the presymptomatic stage of genetically determined parkinsonism. Neurobiol Dis 2010;39:402-408.

  25. Saunders-Pullman R, Hagenah J, Dhawan V, Stanley K, Pastores G, Sathe S, Tagliati M, Condefer K, Palmese C, Brüggemann N, Klein C, Roe A, Kornreich R, Ozelius L, Bressman S. Gaucher disease ascertained through a Parkinson´s center: Imaging and clinical characterization. Mov Disord 2010;25:1364-1372.

  26. Saunders-Pullman R, Stanley K, Brüggemann N, Raymond D, San Luciano M, Wang C, Klein C, Lubarr N, Ozelius L, Bressman SB, Hagenah J (2010) Substantia nigra hyperechogenicity in DYT6 Dystonia: A pilot study. Parkinsonism Relat Disord 2010;16:420-422.

  27. Stanley K, Hagenah J, Brüggemann N, Reetz K, Severt L, Klein C, Yu Q, Derby C, Pullman S, Saunders-Pullman R. Digitized spiral analysis is a prominent marker for Parkinson Disease. Parkinsonism Relat Disord 2010;16:233-234.

  28. Zittel S, Moll CK, Brüggemann N, Tadic V, Hamel W, Kasten M, Lohmann K, Lohnau T, Winkler S, Gerloff C, Schönweiler R, Hagenah J, Klein C, Münchau A, Schneider SA. Clinical neuroimaging and electrophysiological assessment of three DYT6 dystonia families. Mov Disord 2010;25:2405-2412.

  29. Brüggemann N, Klein C. Genetics of Primary Torsion Dystonia. Curr Neurol Neurosci Rep 2010;10:199-206.

  30. Brüggemann N, van der Vegt J, Klein C, Siebner HR. Neurobildgebung genetischer Aspekte der Parkinson-Krankheit. Nervenarzt 2010;81:1196-1203.

  31. Kasten M, Kertelge L, Brüggemann N, van der Vegt J, Schmidt A, Tadic V, Buhmann C, Steinlechner S, Behrens MI, Ramirez A, Binkofski F, Siebner H, Raspe H, Hagenah J, Lencer R, Klein C. Nonmotor symptoms in genetic Parkinson Disease. Arch Neurol 2010;67:670-676.

  32. Arif B, Grünewald A, Fatima A, Ramirez A, Ali A, Brüggemann N, Würfel J, Rolfs A, Lohmann K, Malik A, Klein C, Naz S. An unusual neurological syndrome of crawling gate, dystonia, pyramidal signs and limited speech. Mov Disord 2011;26:2279-83.

  33. Brüggemann N, Hagenah J, Stanley K, Klein C, Wang C, Raymond D, Ozelius L, Bressman S, Saunders-Pullman R. Substantia nigra hyperechogenicity with LRRK2 G2019S mutations. Mov Disord 2011;26:885-888.

  34. Djarmati-Westenberger A, Brüggemann N, Espay AJ, Bhatia KP, Klein C. A novel DCC mutation and genetic heterogeneity in congenital mirror movements. Neurology 2011;77:1580.

  35. Hagenah J, König IR, Kötter C, Seidel G, Klein C, Brüggemann N. Basal ganglia hyperechogenicity does not distinguish between patients with primary dystonia and healthy individuals. J Neurol 2011;258:590-595.

  36. Kasten M, Brüggemann N, König IR, Doerry K, Steinlechner S, Wenzel L, Lohmann K, Klein C, Lencer R. Risk for antipsychotic-induced extrapyramidal symptoms: influence of family history and genetic susceptibility. Psychopharmacology (Berl) 2011;214:729-36.

  37. Osmanovic A, Dendorfer A, Erogullari A, Uflacker N, Braunholz D, Rakovic A, Vierke G, Gil-Rodríguez MC, Münchau A, Albrecht M, Brüggemann N, Gillessen-Kaesbach G, Klein C, Lohmann K, Kaiser FJ. Truncating mutations in THAP1 define the nuclear localization signal. Mov Disord 2011;26:1565-1567.

  38. Rakovic A, Grünewald A, Kottwitz J, Brüggemann N, Pramstaller PP, Lohmann K, Klein C. Mutations in PINK1 and Parkin Impair Ubiquitination of Mitofusins in Human Fibroblasts. PLoS One 2011;6:e16746.

  39. Schneider SA, Ramirez A, Shafiee K, Kaiser FJ, Erogullari A, Brüggemann N, Winkler S, Bahman I, Osmanovic A, Shafa A, Bhatia KP, Najmabadi H, Klein C, Lohmann K. Homozygous THAP1 mutations as a cause of early-onset generalized dystonia. Mov Disord 2011;26:858-861. 

  40. Steinlechner S, Brüggemann N, Sobottka V, Benthien A, Behn B, Klein C, Schmid G, Lencer R. Restless legs syndrome as a possible predictor for psychiatric disorders in parents of children with ADHD. Eur Arch Psychiatry Clin Neurosci 2011;261:285-291.

  41. Zittel S, Kroeger J, van der Vegt J, Siebner HR, Brüggemann N, Ramirez A, Behrens MI, Gerloff C, Bäumer T, Klein C, Münchau A. Motor pathway excitability in ATP13A2 mutation carriers: a transcranial magnetic stimulation study. Parkinsonism Relat Disord 2011;26:2445-2446.

  42. Brüggemann N*, Külper W*, Hagenah J, Bauer P, Pattaro C, Tadic V, Lohnau T, Winkler S, Tönnies H, Sprenger A, Pramstaller P, Rolfs A, Siebert R, Riess O, Vieregge P, Lohmann K, Klein C. Autosomal Parkinson’s disease in a large German pedigree. Acta Scand Neurol 2012; 126:129-137.

  43. Brüggemann N*, Spiegler J*, Hellenbroich Y, Opladen T, Schneider SA, Boor R, Stephani U, Gillessen-Kaesbach G, Sperner J, Klein C. Beneficial prenatal levodopa therapy in autosomal recessive GTP cyclohydrolase I deficiency. Arch Neurol 2012;69:1071-1075. 

  44. Depienne C, Bouteiller D, Méneret A, Billot S, Groppa S, Klebe S, Charbonnier-Beaupel F, Corvol JC, Saraiva JP, Brueggemann N, Bhatia K, Cincotta M, Brochard V, Flamand-Roze C, Carpentier W, Meunier S, Marie Y, Gaussen M, Stevanin G, Wehrle R, Vidailhet M, Klein C, Dusart I, Brice A, Roze E. RAD51 Haploinsufficiency Causes Congenital Mirror Movements in Humans. Am J Hum Genet 2012;90:301-307.

  45. Kasten M, Kertelge L, Tadic V, Brüggemann N, Schmidt A, van der Vegt J, Siebner H, Buhmann C, Lencer R, Kumar KR, Lohmann K, Hagenah J, Klein C. Depression and quality of life in monogenic compared to idiopathic, early-onset Parkinson’s disease. Mov Disord 2012;27:754-759.

  46. Lohmann K, Uflacker N, Erogullari A, Lohnau T, Winkler S, Dendorfer A, Schneider SA, Osmanovic A, Svetel M, Ferbert A, Zittel S, Kühn A, Schmidt A, Altenmüller E, Münchau A, Kamm C, Wittstock M, Kupsch A, Moro E, Volkmann J, Kostic V, Kaiser FJ, Klein C, Brüggemann N. Identification and functional analysis of novel THAP1 mutations. Eur J Hum Genet 2012;20:171-175.

  47. Richter J, Appenzeller S, Ammerpohl O, Deuschl G, Paschen S, Brüggemann N, Klein C, Kuhlenbäumer G. No evidence for differential methylation of α-synuclein in leukocyte DNA of Parkinson patients. Mov Disord 2012;27:590-591.

  48. Hagenah J, Brüggemann N. Basal ganglia sonography: Will it mature into a preclinical diagnostic tool for Parkinson’s Disease? Basal Ganglia, in press.

< Go back